| scholarly article | Q13442814 |
| review article | Q7318358 |
| P2093 | author name string | Joel N Maslow | |
| P2860 | cites work | Update: Severe respiratory illness associated with Middle East Respiratory Syndrome Coronavirus (MERS-CoV)--worldwide, 2012-2013. | Q34653021 |
| Sparse evidence of MERS-CoV infection among animal workers living in Southern Saudi Arabia during 2012. | Q35158287 | ||
| Lack of middle East respiratory syndrome coronavirus transmission from infected camels | Q35229655 | ||
| Generation of a transgenic mouse model of Middle East respiratory syndrome coronavirus infection and disease | Q35487986 | ||
| A double-inactivated severe acute respiratory syndrome coronavirus vaccine provides incomplete protection in mice and induces increased eosinophilic proinflammatory pulmonary response upon challenge | Q35531454 | ||
| High proportion of MERS-CoV shedding dromedaries at slaughterhouse with a potential epidemiological link to human cases, Qatar 2014 | Q35860307 | ||
| Pre- and postexposure efficacy of fully human antibodies against Spike protein in a novel humanized mouse model of MERS-CoV infection | Q35865538 | ||
| Multi-Organ Damage in Human Dipeptidyl Peptidase 4 Transgenic Mice Infected with Middle East Respiratory Syndrome-Coronavirus | Q35877765 | ||
| Evaluation of candidate vaccine approaches for MERS-CoV. | Q35917397 | ||
| A synthetic consensus anti-spike protein DNA vaccine induces protective immunity against Middle East respiratory syndrome coronavirus in nonhuman primates | Q36069589 | ||
| Association of Higher MERS-CoV Virus Load with Severe Disease and Death, Saudi Arabia, 2014. | Q36212118 | ||
| Mortality Risk Factors for Middle East Respiratory Syndrome Outbreak, South Korea, 2015. | Q36212164 | ||
| Middle East Respiratory Syndrome Coronavirus Superspreading Event Involving 81 Persons, Korea 2015. | Q36241778 | ||
| Epidemiologic features of the first MERS outbreak in Korea: focus on Pyeongtaek St. Mary's Hospital | Q36297509 | ||
| Kinetics of Serologic Responses to MERS Coronavirus Infection in Humans, South Korea | Q36353976 | ||
| Costly Lessons From the 2015 Middle East Respiratory Syndrome Coronavirus Outbreak in Korea | Q36365579 | ||
| Multifacility Outbreak of Middle East Respiratory Syndrome in Taif, Saudi Arabia | Q36418205 | ||
| Genomic characterization of a newly discovered coronavirus associated with acute respiratory distress syndrome in humans | Q36432023 | ||
| Characterization and Demonstration of the Value of a Lethal Mouse Model of Middle East Respiratory Syndrome Coronavirus Infection and Disease | Q36433987 | ||
| Experimental Infection and Response to Rechallenge of Alpacas with Middle East Respiratory Syndrome Coronavirus | Q36935333 | ||
| Zika virus infection complicated by Guillain-Barre syndrome--case report, French Polynesia, December 2013 | Q22330748 | ||
| Zika virus emergence in mosquitoes in southeastern Senegal, 2011 | Q22330757 | ||
| Cross-infection enhancement among African flaviviruses by immune mouse ascitic fluids | Q22330830 | ||
| Zika virus infections in Nigeria: virological and seroepidemiological investigations in Oyo State | Q22330859 | ||
| A serological survey of arboviruses in the human population of Senegal | Q22330861 | ||
| A multipurpose serological survey in Kenya. 2. Results of arbovirus serological tests | Q22330875 | ||
| Isolation of Zika Virus from Aedes Aegypti Mosquitoes in Malaysia * | Q22330876 | ||
| Zika virus infection of the central nervous system of mice | Q22330884 | ||
| Twelve isolations of Zika virus from Aedes (Stegomyia) africanus (Theobald) taken in and above a Uganda forest | Q22330886 | ||
| Zika Virus Infection in Pregnant Women in Rio de Janeiro — Preliminary Report | Q23005539 | ||
| Guillain-Barré Syndrome outbreak associated with Zika virus infection in French Polynesia: a case-control study | Q23012849 | ||
| Detection of Zika Virus in Semen | Q24048084 | ||
| Zika Virus Associated with Meningoencephalitis | Q24247064 | ||
| Differential Susceptibilities of Aedes aegypti and Aedes albopictus from the Americas to Zika Virus | Q24261183 | ||
| Zika Virus Targets Human STAT2 to Inhibit Type I Interferon Signaling | Q24261402 | ||
| Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC | Q24329089 | ||
| Neutralizing antibodies against certain recently isolated viruses in the sera of human beings residing in East Africa | Q24471451 | ||
| Immunologic Studies with Yellow Fever and Selected African Group B Arboviruses in Rhesus and Vervet Monkeys | Q24570669 | ||
| Middle East respiratory syndrome coronavirus in bats, Saudi Arabia | Q24596439 | ||
| Dengue virus sero-cross-reactivity drives antibody-dependent enhancement of infection with zika virus | Q24737245 | ||
| Structural basis of potent Zika–dengue virus antibody cross-neutralization | Q24740325 | ||
| High specificity of a novel Zika virus ELISA in European patients after exposure to different flaviviruses | Q25114980 | ||
| Vaccine protection against Zika virus from Brazil | Q25165129 | ||
| Culex pipiens and Aedes triseriatus Mosquito Susceptibility to Zika Virus | Q26247005 | ||
| Protective efficacy of multiple vaccine platforms against Zika virus challenge in rhesus monkeys | Q26248722 | ||
| Prolonged Detection of Zika Virus RNA in Pregnant Women | Q26250264 | ||
| Specificity, cross-reactivity and function of antibodies elicited by Zika virus infection | Q26252507 | ||
| Zika Virus NS4A and NS4B Proteins Deregulate Akt-mTOR Signaling in Human Fetal Neural Stem Cells to Inhibit Neurogenesis and Induce Autophagy | Q26258575 | ||
| Prolonged Shedding of Zika Virus Associated with Congenital Infection | Q26694582 | ||
| Zika Virus and the Guillain–Barré Syndrome — Case Series from Seven Countries | Q26732180 | ||
| Vertical Transmission of Zika Virus in Aedes aegypti Mosquitoes | Q26747237 | ||
| Receptor-binding domain-based subunit vaccines against MERS-CoV | Q26851979 | ||
| Zika Virus: Implications for Public Health | Q27010617 | ||
| Dengue viruses and mononuclear phagocytes. I. Infection enhancement by non-neutralizing antibody | Q27485050 | ||
| Dengue viruses and mononuclear phagocytes. II. Identity of blood and tissue leukocytes supporting in vitro infection | Q27485051 | ||
| Bat origins of MERS-CoV supported by bat coronavirus HKU4 usage of human receptor CD26 | Q27695604 | ||
| In vivo protection against ZIKV infection and pathogenesis through passive antibody transfer and active immunisation with a prMEnv DNA vaccine | Q27901935 | ||
| Rapid Detection Strategies for the Global Threat of Zika Virus: Current State, New Hypotheses, and Limitations | Q27928011 | ||
| Increased Hospitalizations for Neuropathies as Indicators of Zika Virus Infection, according to Health Information System Data, Brazil | Q27928035 | ||
| Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ça Suffit!) | Q28051937 | ||
| Animal models of Middle East respiratory syndrome coronavirus infection | Q28086778 | ||
| Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus | Q28188496 | ||
| Dengue virus antibodies enhance Zika virus infection | Q28353949 | ||
| Zika Virus Antagonizes Type I Interferon Responses during Infection of Human Dendritic Cells | Q28656345 | ||
| Zika virus protection by a single low-dose nucleoside-modified mRNA vaccination | Q28656365 | ||
| Zika Virus Infection and Associated Neurologic Disorders in Brazil | Q29051432 | ||
| Lack of Durable Cross-Neutralizing Antibodies Against Zika Virus from Dengue Virus Infection | Q29051494 | ||
| Infection with MERS-CoV causes lethal pneumonia in the common marmoset | Q21131359 | ||
| Rapid spread of emerging Zika virus in the Pacific area | Q22242651 | ||
| Zika Virus Outbreak on Yap Island, Federated States of Micronesia | Q22250881 | ||
| Outbreak of Exanthematous Illness Associated with Zika, Chikungunya, and Dengue Viruses, Salvador, Brazil | Q22330692 | ||
| Zika Virus Outbreak, Bahia, Brazil | Q22330702 | ||
| Zika: another sexually transmitted infection? | Q22330709 | ||
| Detection of Zika virus in saliva | Q22330713 | ||
| Potential sexual transmission of Zika virus | Q22330722 | ||
| Detection of Zika virus in urine | Q22330729 | ||
| Aedes hensilli as a potential vector of Chikungunya and Zika viruses | Q22330738 | ||
| Zika Virus, French Polynesia, South Pacific, 2013 | Q22330743 | ||
| Evidence of perinatal transmission of Zika virus, French Polynesia, December 2013 and February 2014 | Q22330746 | ||
| Toward Developing a Preventive MERS-CoV Vaccine-Report from a Workshop Organized by the Saudi Arabia Ministry of Health and the International Vaccine Institute, Riyadh, Saudi Arabia, November 14-15, 2015. | Q37169882 | ||
| Intratracheal exposure of common marmosets to MERS-CoV Jordan-n3/2012 or MERS-CoV EMC/2012 isolates does not result in lethal disease | Q37211511 | ||
| Viral RNA in Blood as Indicator of Severe Outcome in Middle East Respiratory Syndrome Coronavirus Infection | Q37288095 | ||
| Introduction of neutralizing immunogenicity index to the rational design of MERS coronavirus subunit vaccines | Q37434385 | ||
| A shorter time interval between first and second dengue infections is associated with protection from clinical illness in a school-based cohort in Thailand | Q37443026 | ||
| Pushing Forward With Zika Vaccines | Q37604641 | ||
| Preventative Vaccines for Zika Virus Outbreak: Preliminary Evaluation | Q37605206 | ||
| Spread, circulation, and evolution of the Middle East respiratory syndrome coronavirus | Q37621643 | ||
| Novel betacoronavirus in dromedaries of the Middle East, 2013. | Q37664558 | ||
| Antibodies against MERS coronavirus in dromedary camels, United Arab Emirates, 2003 and 2013. | Q37664563 | ||
| Receptor variation and susceptibility to Middle East respiratory syndrome coronavirus infection | Q37713959 | ||
| Immunogenicity of Candidate MERS-CoV DNA Vaccines Based on the Spike Protein | Q37717377 | ||
| Fetal brain lesions after subcutaneous inoculation of Zika virus in a pregnant nonhuman primate | Q37720599 | ||
| Viral load kinetics of Zika virus in plasma, urine and saliva in a couple returning from Martinique, French West Indies. | Q39622836 | ||
| A theoretical estimate of the risk of microcephaly during pregnancy with Zika virus infection | Q39691544 | ||
| Characterization of dengue virus infections in a sample of patients suggests unique clinical, immunological, and virological profiles that impact on the diagnosis of dengue and dengue hemorrhagic fever | Q39909329 | ||
| Modified mRNA Vaccines Protect against Zika Virus Infection | Q40049416 | ||
| Vaccine development for emerging virulent infectious diseases | Q40049457 | ||
| Zika virus infection damages the testes in mice | Q40053231 | ||
| Hearing Loss in Infants with Microcephaly and Evidence of Congenital Zika Virus Infection - Brazil, November 2015-May 2016. | Q40055291 | ||
| Likely Sexual Transmission of Zika Virus from a Man with No Symptoms of Infection - Maryland, 2016. | Q40055299 | ||
| Comparison of Test Results for Zika Virus RNA in Urine, Serum, and Saliva Specimens from Persons with Travel-Associated Zika Virus Disease - Florida, 2016. | Q40059095 | ||
| MERS-CoV spike nanoparticles protect mice from MERS-CoV infection | Q40317741 | ||
| Dengue Virus (DV) enhancing antibody activity in preillness plasma does not predict subsequent disease severity or viremia in secondary DV infection | Q40504658 | ||
| Relationship of preexisting dengue virus (DV) neutralizing antibody levels to viremia and severity of disease in a prospective cohort study of DV infection in Thailand | Q40539101 | ||
| Persistence of Antibodies against Middle East Respiratory Syndrome Coronavirus | Q40688031 | ||
| Purified coronavirus spike protein nanoparticles induce coronavirus neutralizing antibodies in mice | Q40744757 | ||
| Viral Shedding and Antibody Response in 37 Patients With Middle East Respiratory Syndrome Coronavirus Infection | Q40911125 | ||
| Protective Efficacy of Recombinant Modified Vaccinia Virus Ankara Delivering Middle East Respiratory Syndrome Coronavirus Spike Glycoprotein | Q41199088 | ||
| Prevalence of Middle East respiratory syndrome coronavirus (MERS-CoV) in dromedary camels in Abu Dhabi Emirate, United Arab Emirates | Q41477234 | ||
| Immunogenicity of an adenoviral-based Middle East Respiratory Syndrome coronavirus vaccine in BALB/c mice | Q41752133 | ||
| Transmission of MERS-coronavirus in household contacts | Q42197387 | ||
| Evidence for camel-to-human transmission of MERS coronavirus | Q42212312 | ||
| MERS-CoV Infection of Alpaca in a Region Where MERS-CoV is Endemic | Q42762388 | ||
| Lack of peripheral memory B cell responses in recovered patients with severe acute respiratory syndrome: a six-year follow-up study | Q43946093 | ||
| Evidence for camel-to-human transmission of MERS coronavirus | Q44480635 | ||
| A roadmap for MERS-CoV research and product development: report from a World Health Organization consultation. | Q50793231 | ||
| Hospital-associated Middle East respiratory syndrome coronavirus infections. | Q51860799 | ||
| Hospital-associated Middle East respiratory syndrome coronavirus infections. | Q54675118 | ||
| Enhancement of Zika virus pathogenesis by preexisting antiflavivirus immunity | Q29196526 | ||
| A live-attenuated Zika virus vaccine candidate induces sterilizing immunity in mouse models | Q29352360 | ||
| Viral and serological kinetics in Zika virus-infected patients in South Korea | Q29364461 | ||
| Adaptive Immune Responses to Zika Virus Are Important for Controlling Virus Infection and Preventing Infection in Brain and Testes | Q29365210 | ||
| Zika Virus Persistence in the Central Nervous System and Lymph Nodes of Rhesus Monkeys | Q29587262 | ||
| Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia | Q29618053 | ||
| Antibody-dependent enhancement of dengue virus growth in human monocytes as a risk factor for dengue hemorrhagic fever | Q29619530 | ||
| Maternal Zika Virus Disease Severity, Virus Load, Prior Dengue Antibodies and their Relationship to Birth Outcomes. | Q30145578 | ||
| Recurrent Potent Human Neutralizing Antibodies to Zika Virus in Brazil and Mexico | Q30145646 | ||
| Rapid generation of a mouse model for Middle East respiratory syndrome | Q30217177 | ||
| Dromedary Camels and the Transmission of Middle East Respiratory Syndrome Coronavirus (MERS-CoV). | Q30252107 | ||
| Bats, civets and the emergence of SARS. | Q30364520 | ||
| Tailoring subunit vaccine immunity with adjuvant combinations and delivery routes using the Middle East respiratory coronavirus (MERS-CoV) receptor-binding domain as an antigen. | Q30368736 | ||
| A Highly Immunogenic and Protective Middle East Respiratory Syndrome Coronavirus Vaccine Based on a Recombinant Measles Virus Vaccine Platform. | Q30378994 | ||
| DNA vaccine encoding Middle East respiratory syndrome coronavirus S1 protein induces protective immune responses in mice | Q30400066 | ||
| Congenital cerebral malformations and dysfunction in fetuses and newborns following the 2013 to 2014 Zika virus epidemic in French Polynesia | Q31073067 | ||
| Clinical course and outcomes of critically ill patients with Middle East respiratory syndrome coronavirus infection | Q33413007 | ||
| Hospital outbreak of Middle East respiratory syndrome coronavirus | Q33642332 | ||
| Duration of antibody responses after severe acute respiratory syndrome | Q33776548 | ||
| MERS coronavirus in dromedary camel herd, Saudi Arabia | Q33816384 | ||
| Infection enhancement of dengue type 2 virus in the U-937 human monocyte cell line by antibodies to flavivirus cross-reactive determinants | Q33912693 | ||
| Geographic distribution of MERS coronavirus among dromedary camels, Africa | Q33950974 | ||
| Host species restriction of Middle East respiratory syndrome coronavirus through its receptor, dipeptidyl peptidase 4. | Q34059153 | ||
| T cell responses are required for protection from clinical disease and for virus clearance in severe acute respiratory syndrome coronavirus-infected mice | Q34120055 | ||
| Receptor usage and cell entry of bat coronavirus HKU4 provide insight into bat-to-human transmission of MERS coronavirus | Q34120263 | ||
| Virus-specific memory CD8 T cells provide substantial protection from lethal severe acute respiratory syndrome coronavirus infection | Q34261999 | ||
| Detection of a novel human coronavirus by real-time reverse-transcription polymerase chain reaction | Q34304123 | ||
| Clinical features and viral diagnosis of two cases of infection with Middle East Respiratory Syndrome coronavirus: a report of nosocomial transmission | Q34347979 | ||
| Rapid development of a DNA vaccine for Zika virus | Q34542032 | ||
| Replication and shedding of MERS-CoV in upper respiratory tract of inoculated dromedary camels | Q34641515 | ||
| P275 | copyright license | Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International | Q24082749 |
| P433 | issue | 12 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Zika virus | Q202864 |
| coronavirus disease | Q18975243 | ||
| emerging communicable disease | Q609748 | ||
| Coronaviridae | Q1134583 | ||
| drug discovery | Q1418791 | ||
| viral vaccines | Q58624061 | ||
| Zika fever vaccine | Q24657950 | ||
| Zika virus infection | Q27043680 | ||
| P1104 | number of pages | 13 | |
| P5008 | on focus list of Wikimedia project | WikiProject Zika Corpus | Q54439832 |
| ScienceSource | Q55439927 | ||
| P304 | page(s) | 2918-2930 | |
| P577 | publication date | 2017-08-28 | |
| 2017-12-02 | |||
| P1433 | published in | Human Vaccines & Immunotherapeutics | Q21072749 |
| P1476 | title | Vaccines for Emerging Infectious Diseases: lessons from MERS coronavirus and Zika virus | |
| P478 | volume | 13 |
| Q93017024 | A Novel Bacterium-Like Particle Vaccine Displaying the MERS-CoV Receptor-Binding Domain Induces Specific Mucosal and Systemic Immune Responses in Mice |
| Q57050781 | Assay Challenges for Emerging Infectious Diseases: The Zika Experience |
| Q91740283 | Cytolytic Perforin as an Adjuvant to Enhance the Immunogenicity of DNA Vaccines |
| Q59350795 | DNA Vaccines-How Far From Clinical Use? |
| Q91576851 | Emerging infectious disease laboratory and diagnostic preparedness to accelerate vaccine development |
| Q61053635 | Role of heparan sulfate in the Zika virus entry, replication, and cell death |
| Q92223803 | Safety and immunogenicity of an anti-Middle East respiratory syndrome coronavirus DNA vaccine: a phase 1, open-label, single-arm, dose-escalation trial |
| Q95577861 | Vaccine against Middle East respiratory syndrome coronavirus |
| Q92130293 | Zika Vaccine Development-Current Progress and Challenges for the Future |
| Q94589646 | [Conducting clinical studies during the epidemics of communicable diseases: perspectives of methodology and health economics] |
Search more.